Hypertriglyceridemia Clinical Trial Insight, Pipeline Assessment, Companies, Emerging Drugs by DelveInsight

 Breaking News
  • No posts were found

Hypertriglyceridemia Clinical Trial Insight, Pipeline Assessment, Companies, Emerging Drugs by DelveInsight

Hypertriglyceridemia Clinical Trial Insight, Pipeline Assessment, Companies, Emerging Drugs by DelveInsight

“Hypertriglyceridemia Pipeline Insights, 2020”

(Albany, US) DelveInsight has launched a new report on “Hypertriglyceridemia Pipeline Insights, 2020”.


Hypertriglyceridemia Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hypertriglyceridemia market. A detailed picture of the Hypertriglyceridemia pipeline landscape is provided, which includes the disease overview and Hypertriglyceridemia treatment guidelines.

The assessment part of the report embraces in-depth Hypertriglyceridemia commercial assessment and clinical assessment of the Hypertriglyceridemia pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertriglyceridemia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.


Some of the Companies:

  • AstraZeneca
  • Amarin Pharma Inc.
  • GlaxoSmithKline
  • Regeneron Pharmaceuticals
  • Acasti Pharma
  • Kowa Research Institute, Inc.
  • And Many Others


Request for Free Sample Report: https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight


Drugs Covered:

  • Epanova (omega-3-carboxylic acids)
  • Vascepa
  • Lovaza (omega-3-acid ethyl esters)
  • Evinacumab
  • CaPre
  • And Many Others


Scope of the Report

  • The Hypertriglyceridemia report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Hypertriglyceridemia across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Hypertriglyceridemia therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Hypertriglyceridemia research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Hypertriglyceridemia.


Request for Free Sample Report: https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight


Hypertriglyceridemia refers to a fasting plasma triglyceride measurement that is increased, typically above the 95th percentile for age and sex along with additional quantitative or qualitative lipoprotein abnormalities. Patients can fluctuate between hypertriglyceridemic states: given appropriate metabolic stress, mild or moderate hypertriglyceridemia can deteriorate into severe hypertriglyceridemia.

The two main sources of plasma triglycerides (also known as triacylglycerol) are exogenous (i.e., from dietary fat)— carried in chylomicrons, and endogenous (from the liver)—carried in very-low-density lipoprotein (VLDL) particles.

HTG can be divided into primary and secondary types. In primary HTG, chylomicrons normally are cleared rapidly from plasma by lipoprotein lipase with apolipoprotein (apo) C-II as a cofactor—familial chylomicronemia (hyperlipoproteinemia type 1, in the Fredrickson system) and primary mixed hyperlipidemia (type 5) are each characterized by the pathologic presence of chylomicrons after a 12–14 h period of fasting—whereas, in secondary HTG, obesity is probably the metabolic stressor most frequently associated with hypertriglyceridemia, although associations with poorly controlled type 2 diabetes and excessive alcohol consumption are also common (associated with a secondary cause/acquired).


Request for Free Sample Report: https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight


Table of Contents:

1. Report Introduction

2. Hypertriglyceridemia 

3. Hypertriglyceridemia Current Treatment Patterns

4. Hypertriglyceridemia – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Hypertriglyceridemia Late Stage Products (Phase-III)

7. Hypertriglyceridemia Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Hypertriglyceridemia Discontinued Products

13. Hypertriglyceridemia Product Profiles

14. Hypertriglyceridemia Key Companies

15. Hypertriglyceridemia Key Products

16. Dormant and Discontinued Products

17. Hypertriglyceridemia Unmet Needs

18. Hypertriglyceridemia Future Perspectives

19. Hypertriglyceridemia Analyst Review  

20. Appendix

21. Report Methodology


Request for Detailed TOC: https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight


Key Questions

  • What are the current options for Hypertriglyceridemia treatment?
  • How many companies are developing therapies for the treatment of Hypertriglyceridemia? 
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Hypertriglyceridemia?
  • How many Hypertriglyceridemia emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Hypertriglyceridemia?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies? 
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Hypertriglyceridemia market? 
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Hypertriglyceridemia?  
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Hypertriglyceridemia therapies? 
  • What are the clinical studies going on for Hypertriglyceridemia and their status?
  • What are the results of the clinical studies and their safety and efficacy? 
  • What are the key designations that have been granted for the emerging therapies for Hypertriglyceridemia? 
  • How many patents are granted and pending for the emerging therapies for the treatment of Hypertriglyceridemia? 


 About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/hypertriglyceridemia-pipeline-insight